Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1527-1532

  Tokuno, Kazuhisa ^a   Hazama, Shoichi ^a   Yoshino, Shigefumi ^a   Yoshida, Shin ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FoxP3; Gastrointestinal cancer; Regulatory T cell

Indexed keywords

CD4 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STOMACH CANCER;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; HUMANS; T-LYMPHOCYTES, REGULATORY;

EID: 67650083202     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. + regulatory T-cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32, 2001. (Pubitemid 33070205)
2. Taylor PA, Noelle RJ and Blazar BR: CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193: 1311-1318, 2001.
3. + regulatory T-cells control Leishmania major persistence and immunity. Nature 420: 502-507, 2002. (Pubitemid 35477041)
4. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T-cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003. (Pubitemid 36182591)
5. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H: Increased populations of regulatory T-cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408, 2003. (Pubitemid 37248397)
6. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T and Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133, 1999.
7. + T-cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
8. Hori S, Nomura T and Sakaguchi S: Control of regulatory T-cell development by the transcription factor Foxp3. Science 299: 1057-1061, 2003. (Pubitemid 36222930)
9. + regulatory T-cells. Nat Immunol 4: 330-336, 2003. (Pubitemid 36432314)
10. + T regulatory cells. Nat Immunol 4: 337-342, 2003.
11. Sobin LH and Wittekind CL: TNM classification of malignant tumors, 6th edition. New York: John Wiley & Sons, 2002.
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T-cells expressing BL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164, 1995.
13. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC: Prevalence of regulatory T-cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002. (Pubitemid 34921025)
14. high regulatory T-cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55: 1064-1071, 2006. (Pubitemid 43800721)
15. + regulatory T-cells in patients with gastrointestinal malignancies: possible involvement of regulatory T-cells in disease progression. Cancer 98: 1089-1099, 2003. (Pubitemid 37022112)
16. high regulatory T-cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T-cells. J Immunol 173: 1444-1453, 2004. (Pubitemid 38924326)
17. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR and June CH: Regulatory CD4(+)CD25(+) T-cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001. (Pubitemid 32691889)
18. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN and Vickers MA: Immunosuppressive regulatory T-cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103: 1755-1762, 2004. (Pubitemid 38268969)
19. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR and June CH: Cutting edge: Regulatory T-cells from lung cancer patients directly inhibit autologous T-cell proliferation. J Immunol 168: 4272-4276, 2002. (Pubitemid 34441324)
20. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C and Piris MA: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T-cells. Clin Cancer Res 11: 1467-1473, 2005. (Pubitemid 40315228)
21. high regulatory T-cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025, 2005. (Pubitemid 41291715)
22. + regulatory T-cells at the single-cell level. Eur J Immunol 35: 1681-1691, 2005. (Pubitemid 40862316)
23. - T-cells. J Clin Invest 112: 1437-1443, 2003. (Pubitemid 38057697)
24. + regulatory T-cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005. (Pubitemid 41716771)
25. von Boehmer H: Mechanisms of suppression by suppressor T-cells. Nat Immunol 6: 338-344, 2005.
26. Fontenot JD and Rudensky AY: A well adapted regulatory contrivance: regulatory T-cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6: 331-337, 2005. (Pubitemid 41716769)
27. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG and Rudensky AY: Regulatory T-cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329-341, 2005. (Pubitemid 40387475)
28. Beyer M and Schultze JL: Regulatory T-cells in cancer. Blood 108: 804-811, 2006.
29. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004. (Pubitemid 39273735)
30. + regulatory T-cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92: 913-920, 2005. (Pubitemid 40462639)
31. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T-cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464, 2005. (Pubitemid 40490158)
32. high T-cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405, 2006. (Pubitemid 44715110)
33. + T-cells. J Exp Med 183: 2669-2674, 1996. (Pubitemid 26192376)
34. Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ and Linehan DC: Increased prevalence of regulatory T-cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 29: 416-424, 2006. (Pubitemid 44288954)
35. Fuss IJ, Boirivant M, Lacy B and Strober W: The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 168: 900-908, 2002. (Pubitemid 34049594)
36. Mason D and Powrie F: Control of immune pathology by regulatory T-cells. Curr Opin Immunol 10: 649-655, 1998. (Pubitemid 28558579)
37. + regulatory T-cell levels in patients with melanoma. Clin Cancer Res 9: 2551-2559, 2003. (Pubitemid 36842096)
38. Wolf D, Rumpold H, Koppelstatter C, Gastl GA, Steurer M, Mayer G, Gunsilius E, Tilg H and Wolf AM: Telomere length of in vivo expanded CD4(+)CD25(+) regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother 55: 1198-1208, 2006.
39. + regulatory T-cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434, 2006. (Pubitemid 44497257)